GHRS Stock Analysis: Buy, Sell, or Hold?
GHRS - GH Research PLC Ordinary Shares
$24.43
-0.44 (-1.77%)
▼
5d:
+9.26%
30d:
+12.63%
90d:
+52.78%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.0/10
Get Alerted When GHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GHRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GHRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GHRS is currently trading at $24.43, which is considered extended relative to its 30-day fair value range of $20.52 to $23.34.
Technical Outlook: Technically, GHRS is in a strong uptrend. Immediate support is located at $21.54, while resistance sits at $25.94.
Market Sentiment: GHRS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.50 (+61.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GHRS is in a strong uptrend. Immediate support is located at $21.54, while resistance sits at $25.94.
Market Sentiment: GHRS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $39.50 (+61.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$20.52 -
$23.34
Company Quality Score
63/100
(BUY)
Options IV Signal
5th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 5th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.7% below Wall St target ($39.50)
Trading Range Analysis
30-Day Trading Range
$20.52 -
$23.34
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.90
(11.9%)
Support & Resistance Levels
Support Level
$21.54
Resistance Level
$25.94
Current Trend
Strong Uptrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.22
Wall Street Target
$39.50
(+61.7%)
Share & Embed Analysis
Last updated: June 03, 2026 8:05 PM ET
Data refreshes hourly during market hours. Next update: 9:05 PM
Data refreshes hourly during market hours. Next update: 9:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
